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ATM = ataxia-telangiectasia mutated gene; BRCA1 = breast cancer gene 1; BRCA2 = breast cancer gene 2; GARP = glycoprotein a repetitions
predominant gene; PCR = polymerase chain reaction.
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Breast cancer, similar to other tumor types, develops as a
result of cumulative genetic and epigenetic changes. It is
well established that the majority of inherited breast and
ovarian carcinomas are due to germline mutations in the
breast cancer gene 1 (BRCA1) and breast cancer gene 2
(BRCA2) tumor suppressor genes [1–4], but these
inherited cases account for less than 5% of all breast
carcinomas. In the far more common sporadic form of the
disease, mutations or deletion of BRCA1 and BRCA2
have not been detected [5]. This contrasts with other
tumor suppressors such as TP53 and adenomatous
polyposis coli in which both germline and somatic
mutations play a role in tumorigenesis.
Although loss of BRCA1 due to promoter hyper-
methylation and loss of heterozygosity has been reported
in a fraction of breast and ovarian carcinomas [6,7], there
is presently no report on how BRCA2 might be impaired
in sporadic tumors. In a recent issue of Cell, Hughes-
Davies and colleagues described the provocative finding
that the EMSY putative oncogene can interact with
BRCA2 and may inhibit its function [8]. If this hypothesis
proves to be correct, then EMSY amplification would
provide a possible explanation for the lack of BRCA2
mutation in sporadic breast cancers and would further
underline the importance of BRCA proteins in breast
tumorigenesis.
The BRCA2 gene encodes a large (3418 amino acids)
protein proposed to function in DNA repair, homologous
recombination, chromatin remodeling, and regulation of
transcription [9–11]. For instance, BRCA2 is recruited to
RAD51-containing nuclear foci after DNA damage, where
BRCA2 participates in DNA repair. Consistent with this
finding, BRCA2 null cells from human tumors as well as
cells from knockout mice are sensitive to ionization
radiation [12–15]. When fused to a heterologous DNA
binding domain, BRCA2 demonstrated the ability to
stimulate transcription [16–18]. However, the physiologic
targets regulated by these putative BRCA2 transactivation
domains, and the physiologic relevance of this function
and its necessity for tumor suppressor activity, are
unknown since all of these studies were performed in vitro
using overexpressed proteins.
A recent study reported that exogenously expressed
BRCA2 can stimulate transcription of androgen receptor-
regulated genes in human 293 cells [19], but the
relevance of this finding in breast tumorigenesis is unclear.
The only evidence for the importance of the BRCA2
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Although the role of the breast cancer gene 2 (BRCA2) tumor suppressor gene is well established in
inherited breast and ovarian carcinomas, its involvement in sporadic disease is still uncertain. The
recent identification of a novel BRCA2 binding protein, EMSY, as a putative oncogene implicates the
BRCA2 pathway in sporadic tumors. Furthermore, EMSY’s binding to members of the ‘Royal Family’ of
chromatin remodeling proteins may lead to a better understanding of the physiological function of
BRCA2 and its role in chromatin remodeling.
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putative transactivation domain is a germline mutation in a
breast and ovarian cancer family that only removes its
putative transactivation domain due to an inframe deletion,
although even in this case the possibility of overall
structural effects cannot be excluded [20].
In the search for proteins that may interact with the
BRCA2 transactivation domain, Hughes-Davies and
colleagues performed a yeast two-hybrid screen and
identified a novel protein they termed EMSY [8]. The
interaction between recombinant and endogenous EMSY
and BRCA2 was confirmed using multiple different
methods, while the consequences of this interaction were
demonstrated in a reporter assay using a BRCA2
transactivation and the GAL4 DNA binding domain fusion
protein. Co-expressing EMSY or its N-terminus portion
was sufficient to suppress transactivation by the
BRCA2–GAL4 fusion protein from a GAL4 promoter.
These results indicate that EMSY may conceal the
BRCA2 transactivation function through direct binding to
its transactivation domain. Based on this observation, the
authors immediately raised the question of whether EMSY
might function as an oncoprotein that compromises
BRCA2 function in sporadic breast and ovarian
carcinomas.
Interestingly, based on its intracellular localization, EMSY,
similar to BRCA2, is also implicated in DNA damage.
Following ionization radiation, Hughes-Davies and
colleagues observed the recruitment of EMSY into nuclear
foci in a murine fibroblast cell line, although this could not
be reproduced in human cells [8]. DNA damage-induced
nuclear foci are thought to be composed of proteins
involved in DNA damage response and repair that
aggregate at the damaged sites to perform repair
functions. Among these proteins, gamma histone 2AX is
one of the earliest to aggregate into nuclear foci [21],
whereas BRCA2 is recruited into the foci at a later time
point [15,22]. EMSY foci were detected shortly after DNA
damage and almost completely colocalized with phospho-
gamma histone 2AX, suggesting a role for EMSY in early
response to DNA damage. Many proteins (e.g. gamma
histone 2AX, BRCA1, and 53BP1) aggregating into the
foci are phosphorylated on S/TQ sites (serine or threonine
followed by glutamine) by the ataxia-telangiectasia
mutated gene (ATM) kinase in response to DNA damage.
Interestingly, EMSY carries similar sites, raising the
possibility that EMSY might be a new ATM substrate.
Whether EMSY foci require BRCA2 (or vice versa), and if
the EMSY–BRCA2 interaction influences BRCA2’s
binding to RAD51 and recombination-coupled DNA
repair, all remain to be determined.
By performing an additional yeast two-hybrid screen using
EMSY as bait, Hughes-Davies and colleagues also
discovered that EMSY can interact with HP1 and BS69,
proteins containing ‘Royal Family’ domains and implicated
in chromatin remodeling [23]. Chromatin remodeling is yet
another cellular process in which BRCA2 has been
implicated [24,25]. Taken together, these data imply that
EMSY may be involved in many cellular functions in which
BRCA2 is thought to play a role, suggesting that the
EMSY–BRCA2 interaction may have physiologic
relevance and may influence the tumor suppressor
function of BRCA2.
The localization of the EMSY gene to chromosome
11q13, a region amplified in ~13% of breast carcinomas
[26,27], provided a clue that EMSY may play a role in
sporadic tumors by acting as an oncogene. In order to test
this hypothesis, Hughes-Davies and colleagues examined
EMSY’s copy number and expression in a panel of breast
cancer cell lines. Using real-time PCR, array comparative
genomic hybridization, and fluorescence in situ
hybridization, they found that EMSY is overexpressed and
amplified in a subset of breast cancer cell lines. Similarly,
they detected EMSY amplification in 7.4–13% of sporadic
breast tumors, but the expression of EMSY in primary
breast tumors was not analyzed.
Moreover, the EMSY copy number is inversely correlated
with survival in a subset of breast cancer patients.
Specifically, the median disease-free survival of patients
with lymph node-negative tumors with EMSY amplification
was 6.4 years versus that of 14 years in cases without
EMSY amplification. This suggests that EMSY amplifica-
tion may have prognostic value in breast cancer, although
the tumor size was still a stronger predictor of outcome
than EMSY amplification and tumor grade was not
analyzed. Moreover, since most amplicons are large and
include many genes, it is notoriously hard to discriminate
the target of an amplicon from genes that just ‘go along for
the ride’. This is especially true for the gene-rich 11q13
amplicon that includes several proven oncogenes like
cyclin D1, glycoprotein a repetitions predominant gene
(GARP), and PAK1. Hughes-Davies and colleagues had
two pieces of evidence to argue that EMSY might be one
of the potential targets of the 11q13 amplicon, at least in a
subset of breast tumors. First, using quantitative real-time
PCR analysis, they demonstrated that while GARP and
EMSY are co-amplified in breast cancer cell lines, only
EMSY appears to be overexpressed in cells with 11q13
copy number gain. Second, GARP/EMSY amplification is
detected in 7–13% of sporadic breast cancers, and in
3–5% of breast tumors GARP/EMSY amplification is not
associated with that of cyclin D1.
Conclusions
Despite compelling evidence, the crucial question of
whether EMSY is a bona fide surrogate for BRCA2
mutation in sporadic cancers still remains to be answered.
Due to the fact that several other BRCA2 interacting203
proteins are mutated or overexpressed in breast cancer
(BubR1, BCCIP alpha, ATM, and Plk1), the
EMSY–BRCA2 interaction can only be one part of the
story. Although EMSY is implicated in many aspects of
BRCA2 function, more work is required to strengthen
these putative links. For example, it would be important to
know whether breast cancer cell lines with EMSY
amplification display some of the phenotypes (radio-
sensitivity and deficiency in homologous recombination)
characteristic of BRCA2 null cells. More evidence is also
needed to prove that EMSY is overexpressed and
amplified in primary breast and ovarian carcinomas.
Moreover, it would be important to know in which breast
cancer subtypes EMSY amplification occurs and what is
the status of EMSY in BRCA2 null tumors. Experimental
models in cell lines and transgenic mice are desired to
prove the functional relevance of EMSY amplification and
overexpression, and whether it is a target of the 11q13
amplicon.
Nevertheless, with a new partner at hand, the BRCA2 field
is ready for a new dance and members of the ‘Royal
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